Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
10.3343/alm.2018.38.2.147
- Author:
Eunyoung LEE
1
;
Kyoung Joo LEE
;
Hyein PARK
;
Jin Young CHUNG
;
Mi Na LEE
;
Myung Hee CHANG
;
Jongha YOO
;
Hyewon LEE
;
Sun Young KONG
;
Hyeon Seok EOM
Author Information
1. Center for Hematologic Malignancy, National Cancer Center, Goyang, Korea. hseom@ncc.re.kr ksy@ncc.re.kr
- Publication Type:Original Article
- Keywords:
Digital droplet PCR;
JAK2 V617F mutation;
Myeloproliferative neoplasms
- MeSH:
Bone Marrow;
Diagnosis;
DNA;
Follow-Up Studies;
Gene Frequency;
Humans;
Polymerase Chain Reaction*
- From:Annals of Laboratory Medicine
2018;38(2):147-154
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: JAK2 V617F is the most common mutation in myeloproliferative neoplasms (MPNs) and is a major diagnostic criterion. Mutation quantification is useful for classifying patients with MPN into subgroups and for prognostic prediction. Droplet digital PCR (ddPCR) can provide accurate and reproducible quantitative analysis of DNA. This study was designed to verify the correlation of ddPCR with pyrosequencing results in the diagnosis of MPN and to investigate clinical implications of the mutational burden. METHODS: Peripheral blood or bone marrow samples were obtained from 56 patients newly diagnosed with MPN or previously diagnosed with MPN but not yet indicated for JAK2 inhibitor treatment between 2012 and 2016. The JAK2 V617F mutation was detected by pyrosequencing as a diagnostic work-up. The same samples were used for ddPCR to determine the correlation between assays and establish a detection sensitivity cut-off. Clinical and hematologic aspects were reviewed. RESULTS: Forty-two (75%) and 46 (82.1%) patients were positive for JAK2 V617F by pyrosequencing and ddPCR, respectively. The mean mutated allele frequency at diagnosis was 37.5±30.1% and was 40.7±31.2% with ddPCR, representing a strong correlation (r=0.9712, P < 0.001). Follow-up samples were available for 12 patients, including eight that were JAK2 V617F-positive. Of these, mutational burden reduction after treatment was observed in six patients (75%), consistent with trends of hematologic improvement. CONCLUSIONS: Quantitative analysis of the JAK2 V617F mutation using ddPCR was highly correlated with pyrosequencing data and may reflect the clinical response to treatment.
